Mesenchymal Stem Cells: Revisiting History, Concepts, and Assays  by Bianco, Paolo et al.
Cell Stem Cell
CommentaryMesenchymal Stem Cells:
Revisiting History, Concepts, and Assays
Paolo Bianco,1,2,5,* Pamela Gehron Robey,3,5 and Paul J. Simmons4,5
1Department of Experimental Medicine and Pathology, La Sapienza University, 00161 Rome, Italy
2Biomedical Science Park San Raffaele, 00128 Rome, Italy
3Craniofacial and Skeletal Diseases Branch, Department of Health and Human Services, National Institute of Dental
and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
4Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
5These authors contributed equally to this work.
*Correspondence: paolo.bianco@uniroma1.it
DOI 10.1016/j.stem.2008.03.002The concept of mesenchymal stem cells has gained wide popularity. Despite the rapid growth of the field,
uncertainties remain with respect to the defining characteristics of these cells, including their potency and
self-renewal. These uncertainties are reflected in a growing tendency to question the very use of the term.
This commentary revisits the experimental origin of the concept of the population(s) referred to asmesenchy-
mal stem cells and the experimental framework required to assess their stemness and function.The concept of stem cells originated at the end of the 19th cen-
tury as a theoretical postulate to account for the ability of certain
tissues (blood, skin, etc.) to self-renew for the lifetime of an or-
ganism even though they are comprised of short-lived cells.
Many years later, identification of stem cells as discrete cellular
entities followed from the development of methods for prospec-
tive isolation of stem cell candidates, in parallel with the design
of rigorous bioassays to test their potency after transplantation
in vivo.
The currently popular concept of mesenchymal stem cells
(MSCs, a term first coined in Caplan [1991]) can be traced to
classical experiments demonstrating that transplantation of bone
marrow (BM) to heterotopic anatomical sites results in de novo
generation of ectopic bone and marrow. Whereas examples of
such studies date back to the 19th century (Goujon, 1869), the
work of Tavassoli and Crosby clearly established proof of an in-
herent osteogenic potential associated with BM (Tavassoli and
Crosby, 1968). Because these experiments were conductedwith
entire fragments of bone-free BM, the precise identity of any cell
functioning as a progenitor of differentiated bone cells (and
therefore of nonhematopoietic, mesenchymal cells) could not
be delineated. It was Friedenstein and coworkers, in a series of
seminal studies in the 1960s and 1970s (reviewed in Frieden-
stein, 1990), who demonstrated that the osteogenic potential,
as revealed by heterotopic transplantation of BM cells, was as-
sociated with a minor subpopulation of BM cells. These cells
were distinguishable from the majority of hematopoietic cells by
their rapid adherence to tissue culture vessels and by the fibro-
blast-like appearance of their progeny in culture, pointing to their
origin from the stromal compartment of BM. In addition to estab-
lishing BM stroma as the haystack in which to search for the pro-
verbial needle, the work of Friedenstein and coworkers provided
a secondmajor breakthrough by showing that seeding of BMcell
suspensions at clonal density results in the establishment of dis-
crete colonies initiated by single cells (the colony-forming unit
fibroblastic, CFU-Fs [Friedenstein et al., 1970]). The clonal nature
of each colony was demonstrated by the linear dependence of
colony formation on the number of cells explanted, the useof chromosomal markers, 3H-thymidine labeling, through time-
lapse photography, and by Poisson distribution statistics (Frie-
denstein, 1976; Friedenstein et al., 1970, 1974; Gronthos et al.,
2003). In vivo transplantation led to the recognition that multiple
skeletal tissues (bone, cartilage, adipose tissue, and fibrous tis-
sue) could be experimentally generated, in vivo, by the progeny
of a single BM stromal cell (reviewed in Friedenstein, 1990). Frie-
denstein and Owen called this cell an osteogenic stem cell
(Friedenstein et al., 1987) or a BM stromal stem cell (Owen and
Friedenstein, 1988).
The implications of these discoveries were initially appreciated
solely in experimental hematology and only later for their rele-
vance to bone biology and disease. As conceptualized by the
stem cell niche hypothesis proposed by Schofield (1978), the
notion that hematopoietic stem cells (HSCs) are regulated by
their physical association with a discrete cellular microenviron-
ment within BM was substantiated by the seminal observations
of Dexter, Allen, and colleagues (Allen, 1978; Dexter et al.,
1977; Dexter and Testa, 1976). Stemming from a long-standing
quest to elucidate the functional relationship between HSCs
and some physical component of the bone/BM organ, the pio-
neering work of Tavassoli and of Friedenstein and Owen re-
vealed that a second type of stem cell could be present in the
BM and, specifically, in the hematopoiesis-supporting stroma.
Although the hypothesis was firmly established, and the sup-
porting experimental evidence was published and widely repro-
duced, the concept of a nonhematopoietic stem cell in BM did
not resonate worldwide until additional similar work was pub-
lished in 1999 (Pittenger et al. [1999], from a commercial entity,
Osiris Therapeutics, Inc). Combined with the timing of the isola-
tion of human embryonic stem (ES) cells, the term mesenchymal
stem cell (MSC), proposed previously as an alternative to ‘‘stro-
mal’’ or ‘‘osteogenic’’ stem cell (Caplan, 1991; as applied to cells
ex vivo), gained wide popularity. In theminds of many, MSCs be-
came one kind of postnatal human stem cell with a differentiation
potential that would be broader than originally envisioned or per-
haps even as broad as that of ES cells. This assumption, echoed
in later studies claiming transgermal potential (‘‘plasticity’’) ofCell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 313
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et al., 2002; Lakshmipathy and Verfaillie, 2005; Poulsom et al.,
2002), evoked attention and also generated confusion, and it re-
mains highly controversial (Bianco, 2007; Wagers et al., 2002).
The notion of the MSC evolved from the historical roots of the
conceptualized nonhematopoietic stem cell present in BM. Un-
beknown to the vast majority of current workers in the MSC field,
these roots, together with general basic tenets of stem cell biol-
ogy, set precise limits as to how the biology of MSCs should
be assessed, how the stem cell concept might be applied,
what their envisioned clinical applications could be, and what
nomenclature would be most appropriate.
Is ‘‘Mesenchymal Stem Cell’’ a Proper Term?
Questions have been raised over the usage of the term ‘‘mesen-
chymal stem cells’’ (Dominici et al., 2006; Horwitz et al., 2005),
but there are multiple reasons that indicate it is inappropriate.
First, the original naming of this class of stem cells as mesenchy-
mal was based on the hypothesis that multiple tissues beyond
skeletal lineages could be generated by postnatal MSCs, includ-
ing skeletal muscle, myocardium, smooth muscle, tendon, etc.
(reviewed in Caplan, 2005). However, the nonskeletal potential
of single MSCs has not been formally proven in vivo, and the
point remains controversial. Second, during prenatal organo-
genesis, the series of tissues regarded bymany as related by line-
age to postnatal MSCs are generated by a system of distinct
progenitors, rather than from a common ancestor. Bone and
skeletal muscle arise from distinct progenitors. In fact, bone as
a tissue develops from neuroectodermal progenitors (craniofa-
cial bones) or from axial and lateral specifications of the meso-
derm (reviewed in Olsen et al., 2000). In addition, although neuro-
ectoderm gives rise to a transient embryonic population of cells
with properties of MSCs (Takashima et al., 2007), postnatal pro-
genitors (and MSCs) have a distinct origin, which has yet to be
defined.
Nonetheless, the term has gained such global usage that it
would perhaps be futile to suggest replacing it with another
that would better adhere to the known biology of the system. De-
bating nomenclature always conveys a flavor of pedantry. How-
ever, debating misconceptions that accompany the popular use
of any term may correct flawed experimental approaches based
on mistaken assumptions, may trigger experimental advances,
and may ultimately promote better understanding. The term
MSC is indeed questioned, and questionable, because it con-
veys assumptions that were neither included in the original con-
cept of nonhematopoietic stem cells in the BM nor supported
by direct experimental evidence. These assumptions revolve
around multipotency and self-renewal, the two defining charac-
teristics of a stem cell, and also around the experimental assays
relevant to both properties, as well as to additional criteria (such
as, for example, clonogenicity). Furthermore, whereas the origi-
nal notion of MSCs specifically referred to cells in BM (bone
marrow stromal cells, BMSCs), the current notion has been
extended to include cells from additional sources (such as syno-
vium, adipose tissue, dental pulp, etc.) and, indeed, from almost
every postnatal connective tissue. On the whole, uncertainty
over the usage of the term MSC reflects, and arises from, impre-
cision in the use of a system of terms and experimental assays
(Table 1).314 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.How Should MSCs and Their Properties Be Assayed?
The current highest state of the art assay to establish stem cell
function is exemplified by the capacity of a single prospectively
isolated HSC to reconstitute, serially and long term, multilineage
hematopoiesis in lethally irradiated recipient mice. The crucial
general lessons from such stringent and rigorous assays are
that (1) stemness is probed through in vivo transplantation ex-
periments, (2) multipotency can only be probed at the single-
cell level, and (3) self-renewal means reconstitution of a stem
cell population identical in phenotype and function to the one
originally explanted. The relative ease and efficacy of assaying
HSCs derives in part from the ability of prospectively isolated
HSCs to circulate and home to their permissive niche, the contin-
uous and rapid turnover of HSCs and their progeny, and the sys-
temic rather than localized distribution of hematopoiesis across
the body. Some of these inherent biological properties of the
HSC system are not necessarily duplicated either in the BMSC
system or in other systems in which definitions of stemness are
sought. For example, single HSCs can be transplanted in vivo
via the circulation and distributed at high efficiency without
ex vivo culture. On the other hand, sufficient numbers of BMSCs
necessary to regenerate a skeletal defect typically need to be lo-
cally transplanted, and even prospectively isolated, single skel-
etal progenitors need to be cultured to generate sufficient num-
bers of cells prior to transplantation. Furthermore, the capacity
for self-renewal undoubtedly relates to the rate of tissue turn-
over. Whereas skin in its entirety turns over every 30 days,
the whole skeleton turns over three to five times during adult-
hood. Consequently, self-renewal of stem cells capable of re-
forming skeletal tissues, in nature, would not be expected to in-
volve the same number of cell divisions as for HSCs or epidermal
stem cells. Assessing self-renewal and multipotency (the defin-
ing characteristics of all postnatal stem cells) of nonhemato-
poietic stem cells thus requires the development and use of
in vivo assays based on the same rigorous principles as in HSC
bioassays, but adapted to the specific biology of the system
under study. How do these considerations relate to MSCs?
Identification and Expansion in Culture
Classically, a subset of BMSCs is designated as clonogenic if it is
able to generate colonies of fibroblast-like cells from single cells
when plated in culture. Importantly, colony growth can be ob-
served when cells are plated at higher, nonclonal density, but
in this case, colonies cannot be assumed to be clonal, and enu-
meration or analysis of colonies formed under nonclonal condi-
tions is experimentally meaningless. As assessed by current
CFU-F assays, clonogenicity of BMSCs reflects the ability of
a cell to grow in a density-insensitive fashion. Of note, any gen-
uine stem cell within the BM stromawould be clonogenic, but the
reverse statement is not valid, as only a fraction of CFU-Fs are
multipotent based on in vivo transplantation (Bianco and Robey,
2004; Gronthos et al., 2003). No markers are available to distin-
guish multipotent CFU-Fs from more committed ones, but the
frequency of CFU-Fs does correlate with the incidence of pro-
genitors in a given BM sample. Clonogenic BMSCs can be en-
riched by using surface markers such as STRO-1 (Simmons
and Torok-Storb, 1991) or MCAM (Sacchetti et al., 2007). How-
ever, as long as experimentation requires the use of cultured
cells, sorting clonogenic progenitors by surface phenotype or
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Term Definition Term Definition
Bone marrow
stromal cells
(in situ)
-Extravascular cells of nonhematopoietic,
nonendothelial lineages.
Multipotent
mesenchymal
stromal cell
(MSCs)
-An alternative name for MSCs.
-Highlight their multilineage potential.
-Physically associated with hematopoietic cells in BM. -Underscores their questionable stemness due to lack
of evidence for self-renewal.-Providecues for thehoming, retention,proliferation, and
differentiation of hematopoietic stem/progenitor cells.
-Include adventitial reticular cells, marrow adipocytes,
developing and mature osteogenic cells, and
pericytes/mural cells.
Bone marrow
stromal cells
(in vitro,
BMSCs)
-Cultured cell strains derived from explantation of
adherent, nonhematopoietic, nonendothelial BM cells.
Pericyte,
mural cell
-Subendothelial, nonendothelial cell in the
microvascular wall.
-Express MCAM, BG5, a-smooth muscle actin,
otherwise defined histologically.
-May be initiated by one or more CFU-Fs, by stromal
cells seeded at non-clonal density, or by cells sorted
by phenotype. -Can be derived frommesoderm or ectomesenchyme.
-A putative progenitor for connective tissues.-Some BMSCs are CFU-Fs.
Colony
(fibroblastic)
-The in vitro clonal progeny of a CFU-F. Self-renewal -The ability to generate cells identical in phenotype and
potency to the starting cell population.-Appears as a discrete colony of 50 or more
fibroblast-like cells. -Occurs when one cell divides to generate one stem
cell and one nonstem cell.-Not a CFU-F.
-Can only be assayed via in vivo transplantation of
homogeneous populations.
-For connective tissues, has been shown for adventitial
reticular cells and some CFU-Fs in the human bone
marrow and satellite cells in murine skeletal muscle.
-Does not imply infinite or continuous cell division
in vivo or in vitro.
-A defining property of postnatal stem cells.
Colony
forming unit-
fibroblastic
(CFU-F)
-A single cell, freshly isolated from an intact tissue. Skeletal stem cell,
stromal stem cell,
osteogenic
stem cell
-The postnatal multipotent and self-renewing
progenitor of skeletal tissues (bone, cartilage, bone
marrow adipocytes, fibroblasts, and bone marrow
stromal cells).
-Able to initiate clonal growth of fibroblastic cells at low
density.
-Designated according to tissue of origin: BM-CFU-F,
[any tissue]- CFU-F. -Found in the bone marrow stroma.
-Has been assayed in vivo at clonal level.
Expansion (of
stem cells)
-The absolute increase in stem cell number within a cell
population.
Stroma -Anatomical term referring to the supporting (often
connective) tissue in any organ.
-Occurs when one cell divides to generate two
identical stem cells.
-Serves a trophic and mechanical function for the
specialized cell types of that organ (parenchyma).
-Expansion of a whole culture of BMSCs is not
equivalent to expansion of the stem cells therein.
Mesenchymal
stem cell
(MSCs)
-A conceptual postnatal progenitor of most if not all
derivatives of mesoderm.
[Any Tissue]
Stromal cells
-Fibroblastic populations established in culture from
any tissue.
-Lineage potential includes skeletal (bone, cartilage,
fat, tendon) and nonskeletal (smooth muscle, skeletal
muscle, and possibly myocardium and endothelial
cells) tissues.
-Likely derived from the stroma/connective tissue of
the originating organ.
-Postulated to exist in BM, liver, synovium, adipose
tissue, heart, and other postnatal connective tissues.
-Suggested to include a subset of pluripotent cells.
-Often used to denote cultured cells from almost any
connective tissue.
Mesenchyme -A primitive embryonic loose connective tissue.
-An embryonic subset of mesoderm-derived cells.
-Also a subset of neuroectoderm-derived cells
(ectomesenchyme).Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 315
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meaning (Sacchetti et al., 2007). Consequently, the investigative
value of isolation procedures based on surface phenotype will
only unfold after in vivo assays are developed for the use of
uncultured clonogenic progenitors.
Adherent cells capable of density-independent growth are
found in a number of nonhematopoietic tissues, such as perios-
teum and dental pulp, and probably in all connective tissues, and
are also called CFU-Fs in the literature. In addition, it has been
reported that some nonhematopoietic tissues have higher fre-
quencies of CFU-Fs compared to BM. However, because such
tissues contain very few hematopoietic cells against which BM
CFU-F frequencies are calculated, they may not harbor relatively
more clonogenic cells over BM.
Importantly, a primary culture of BMSCs can be established at
clonal or nonclonal density (in most of the current literature, the
latter is the case). In the first instance, the entire culture repre-
sents the progeny of CFU-Fs. In the second instance, the
primary culture includes cells derived from nonclonogenic, ad-
herent cells with limited but demonstrable potential for growth.
Thus, primary cultures established at clonal or nonclonal density
are remarkably different, but neither type of culture should be
called a culture of stem cells, mesenchymal or otherwise quali-
fied. Expansion of monoclonal or multiclonal primary cultures
can yield populations that are homogeneous in the expression
of certain markers, but not others. Functionally, within clonal cul-
tures, the initially multipotent cells do self-renew (Sacchetti et al.,
2007), and may even stochastically expand, to some extent.
However, simultaneously and within the same culture, some of
the progeny of the culture-initiating cells differentiate or even
senesce. Thus, any culture of nontransformed mammalian cells
is heterogeneous due to inherent kinetics, as the expansion of
stem cells within the culture is neither the sole nor the predomi-
nant event. The stochastic frequency of this event with respect to
commitment or senescence in culture is as yet undefined; con-
sequently, the expansion of stem cells cannot be measured or
simply inferred from growth of the whole culture.
One implication of this trait is that, although one can purchase
commercial cultures of MSCs, they are more accurately de-
scribed as cultures of BMSCs and may or may not include a
proportion of multipotent and self-renewing cells. In addition,
manymodifications of the original simple culture conditions have
been proposed to improve the expansion of MSCs in culture.
However, measuring in vitro expansion of stem cells requires
in vivo assays at the single-cell level, at least until such time
that a phenotypic marker is identified that defines the stem cell
pool. Therefore, to truly claim ex vivo expansion, the progeny
of single original CFU-Fs isolated after expansion would need
to be transplanted in vivo and comparatively evaluated for the
formation of different tissues. This is admittedly demanding,
and has never been done, so it remains unclear whether any pro-
posed cocktail for BMSC expansion indeed promotes expansion
of stem cells within the population, rather than simply promot-
ing the growth of the entire BMSC population as a whole and
possibly even depleting the stem cell subset contained within it.
Differentiation Potential
It is solidly established by the work of Friedenstein and others
that a subset of single BMSCs is multipotent and therefore316 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.displays one property commonly found in stem cells. However,
the same studies indicate that this subset is limited to differenti-
ation into skeletal cell types found at different developmental
stages as well as at specific anatomical sites. These include
osteoblasts (bone), chondrocytes (cartilage), adipocytes (BM
stroma), fibroblasts (periosteum), and adventitial reticular cells
(BM stroma). Although the claim that BMSCs can also give rise
to additional cell types of mesodermal origin (skeletal muscle,
smooth muscle, cardiac muscle, endothelial cells, etc.) is com-
monplace, this claim is not rooted in equally solid experimental
evidencewith heterotopic transplantation of the progeny of a sin-
gle cell and thus remains controversial. Even greater controversy
exists over the claims of transgermal potential of either BMSCs
or subsets thereof (Beltrami et al., 2007; Jiang et al., 2002). It is
for these reasons that it would be appropriate to use the term
‘‘skeletal stem cells’’ for BM-derived, multipotent stromal cells
capable of generating skeletal cell types in vivo (Bianco and
Robey, 2004).
Beyond the BM, adherent cells capable of density-indepen-
dent growth are found in a number of nonhematopoietic connec-
tive tissues, such as periosteum and dental pulp, and are also
called CFU-Fs in the literature. However, the potency of CFU-
Fs from nonhematopoietic tissues and BM has not been com-
pared systematically by in vivo assays, and prevailing evidence
suggests that CFU-Fs from different tissues are not the same.
For example, when grown and transplanted in vivo under condi-
tions identical to those used for BMSCs, CFU-Fs from dental
pulp form dentin rather than bone (Gronthos et al., 2002). Thus,
rather than a uniform, single class of ubiquitous MSCs, the evi-
dence points to a varied class of clonogenic progenitors found
in different tissues but endowed with tissue-specific potency.
No matter what the source of the stromal population being
examined, multipotency of MSCs is commonly believed to be
assessable by in vitro differentiation assays. However, these as-
says correlate poorly with results of in vivo differentiation assays,
even when conducted in parallel on the same cell strain
(reviewed in Bianco et al., 2006). Furthermore, multipotency
(a property of a single cell) cannot be determined based on as-
says conducted on nonclonal cell strains in culture. In vitro gen-
eration of alizarin red deposits (osteogenesis), oil redO-stainable
cells (adipogenesis), and alcian blue-stainable matrix (chondro-
genesis) in parallel cultures of nonclonal strains of BM stromal
cells, or any strain of cells, does not predict multipotency (Bianco
et al., 2006; Gronthos et al., 2002), as commonly assumed in
a copious literature, and therefore does not identify any cell cul-
ture as a culture of stem cells, no matter how further qualified by
any name of choice.
Assaying Self-Renewal
In addition to the significant misconceptions of multipotency and
of in vitro assays to probe it, even greater ambiguities persist
concerning the generally assumed self-renewal of stem cells
within BM stroma or within any other connective tissue. In
most studies, self-renewal is equated to sustained growth in cul-
ture or, in some scenarios, is assumed based on retention of in
vitro differentiation after multiple population doublings. How-
ever, the only system for which stem cell self-renewal is consid-
ered to be solidly proven is the hematopoietic system, based on
the ability of phenotypically defined HSCs to serially reconstitute
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et al., 1996; Spangrude et al., 1988; Weissman, 2000). Notably,
this property is associated with no ex vivo proliferation. Demon-
stration of self-renewal postulates the reconstitution in vivo of
a stem cell compartment with phenotype and properties identi-
cal to the starting population. Evidence for self-renewal of pro-
genitors within the BMSC population has only very recently
started to emerge (Sacchetti et al., 2007) and does indeed sup-
port the concept that such cells include a bona fide stem cell,
and it also addresses the previous lack of direct experimental
evidence for the ability of stromal cells to self-renew (Dominici
et al., 2006; Horwitz et al., 2005). Whether this trait is shared
by CFU-F-forming populations isolated from other connective
tissues remains to be seen.
A Putative Marker
It is often assumed that expression of a certain broad set of
markers defines various types of cell cultures asMSCs, but in re-
ality, most of these markers are expressed by cultures of fibro-
blastic cells from any tissue. In addition, most if not all such
markers are highly modulated in culture, which underscores
the futility of efforts to characterize stromal cell cultures per se.
In contrast, the original quest for markers of the putative nonhe-
matopoietic BM stem cell focused on those that could identify
the CFU-F among uncultured BM cells. Along with the classical
STRO-1 epitope, a number of other markers can assist in enrich-
ing CFU-Fs (e.g., MCAM, CD105). However, in addition to
markers of uncultured CFU-Fs, markers of cells in situ are partic-
ularly needed (1) when seeking the in situ counterpart of CFU-Fs
and (2) to follow the fate of cells transplanted in vivo, particularly
when aiming for evidence of self-renewal. MCAM appears to be
one such marker.
In human BM, MCAM marks adventitial reticular cells (Sac-
chetti et al., 2007), a classically known stromal cell type residing
in a subendothelial position over the abluminal surface of BM
sinusoids (Westen and Bainton, 1979). In other tissues, MCAM is
expressedbypericytes (Li et al., 2003), an elusive cell type recog-
nized by their anatomy and position rather than by any precisely
defined phenotype. Like BM adventitial reticular cells, pericytes
reside on the abluminal surface of endothelial cells in the micro-
vasculature of every connective tissue. Given this broad distribu-
tion, and that pericytes may represent the in situ counterpart of
BM CFU-Fs, one could hastily conclude that pericytes are the
MSCs found in different tissues. Using MCAM to identify the
pericyte population will aid in determining whether CFU-Fs
from nonhematopoietic tissues are indeed pericytes. If so, it will
be possible to test the hypothesis that MSCs exist in all connec-
tive tissues, and to determine whether their capacity to function
in clonogenic and in vivo assays is consistent regardless of their
tissue of origin. In this regard, pericytes isolated from skeletal
muscle are spontaneously myogenic in vitro (Dellavalle et al.,
2007) and nonosteogenic in vivo, in sharp contrast with BM
CFU-FsandwithBMsubendothelial cells despite their coincident
anatomical identity. Thus, as with the potency of CFU-Fs derived
fromdifferent tissues, current evidence regardingpericytes in dif-
ferent tissues seems to reflect a system of organ-specific pro-
genitors with organ-specific potency. Nonetheless, studies of
pericytebiologymayprovide clues as to thedevelopmental origin
of postnatal progenitor/stem cells in nonhematopoietic tissues.Composing Diversity into a Unifying Model
The assumed existence of a homogeneous stromal stem cell
population present in multiple mesenchyme-derived tissues re-
mains open to question. Using the example of pericytes as
a model, a hypothesis can be generated such that the seeding
of definitive postnatal progenitors within connective tissues
may be rooted in the general mechanisms whereby pericytes
are recruited to the nascent microvascular wall during develop-
ment and postnatal growth (Figure 1). In this view, stemness of
these cells could be interpreted as a byproduct of a general de-
velopmental mechanism, whereby local cells committed to an
organ-specific fate (e.g., myogenic in muscle, skeletogenic in
BM) are recruited to nascent microvascular walls during devel-
opment and postnatal growth (Jain, 2003). As a result, these cells
would be retained in a growth-arrested state until triggered to re-
sume proliferation and differentiation, either in response to phys-
iological cues, as in tissue turnover or repair, or experimentally,
when explanted in vitro as CFU-Fs. Subendothelial osteoproge-
nitors are recruited to become stem cells in a somewhat acci-
dental way, and they incidentally serve specific functions char-
acteristic of pericytes in different postnatal tissues. Or, as an
alternative to differentiation, tissue-specific stem cells may func-
tion to support the regeneration of other local cell types, as seen
in BM.
In BM, BMSCs serve two functions. One is the classically rec-
ognized function of providing a supportive microenvironment for
hematopoiesis. The other is related to the development, stabili-
zation, and maintenance of the sinusoidal network (Sacchetti
et al., 2007), consistent with their subendothelial localization. In
the bone/BM organ, the two functions are closely intertwined.
Hematopoiesis requires establishment of a sinusoidal network,
and HSCs localize to sinusoidal walls (Kiel and Morrison,
2006), in addition to endosteal surfaces (Haylock et al., 2007).
BMSCs also localize to sinusoidal walls, and when hematopoi-
etic development is modeled in vivo, they do so prior to the es-
tablishment of hematopoiesis (Sacchetti et al., 2007). In addition,
BMSCs rank as committed, but not differentiated, osteogenic
progenitors. In view of the emerging role of osteogenic cells in
providing a niche for HSCs (Arai et al., 2004; Calvi et al., 2003;
Zhang et al., 2003), these data portray an appealing avenue for
research into a unique, dual system of stem/progenitor cells
that functionally interact in the regulation of hematopoiesis and
bone physiology. Furthermore, beyond the BM, studies over
the past 10 years have attempted to demonstrate that transplan-
tation of BMSCs into nonskeletal (unorthodox) sites would result
in repair of myocardium, brain, and more (reviewed in Barry,
2003). However, although evidence for the ability of transplanted
BMSCs to generate differentiated nonskeletal tissue cell types
(e.g., cardiomyocytes, neurons, etc.) has been controversial,
a beneficial effect on the function of target organs has often
been observed (reviewed in Phinney and Prockop, 2007; Picinich
et al., 2007). It may be that BMSC transplantation consists of ex-
porting the inherent biological function(s) that BMSCs exert in
BM to unorthodox sites. That is, if one function is to nurture
HSCs and their progeny, then it is possible that nonhemato-
poietic cells may also benefit from a ‘‘nursing’’ effect conveyed
by direct interaction with BMSCs and/or by paracrine stimuli
(Caplan and Dennis, 2006). The immune-modulatory activity of
BMSCs, supported by a number of studies (e.g., Ren et al.,Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 317
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Serve as a Reservoir of Tissue-Specific
Progenitors
The recruitment of local tissue progenitors as mu-
ral cells/pericytes in different tissues such as bone
marrow and skeletal muscle is depicted.
(A) During development, local osteogenic cells
(osteoblasts, left side) in the BM associate with
the vascular wall as subendothelial mural cells/
pericytes (adventitial reticular cells in sinusoids).
In the postnatal organ, these cells can be ex-
planted and assayed as clonogenic skeletal pro-
genitors (bone, right side).
(B) Blood vessels associate with local myogenic
progenitors in developing muscle, which are re-
cruited into being pericytes (myocytes, left side).
Consequently, pericytes isolated from the micro-
vasculature of skeletal muscle will exhibit myo-
genic potential (muscle, right side). Therefore,
this model predicts that although pericytes in dif-
ferent connective tissues may arise by a common
developmental pathway and share anatomic iden-
tity, their differentiation capacity is likely to be
tissue specific.2008), may be seen as part of the pleiotropic influence of BM
stromal cells on cells of hematopoietic lineage. Likewise, the
functional effect of BMSCs on vascular structure, integrity,
stability, or regeneration may also be retained in unorthodox
BMSC transplantation, resulting in a serendipitous benefit for
organ function.
What’s in a Name—or Many?
Although the concept that a bona fide stem cell can be found in
BM stroma has withstood the test of time and has actually
gained momentum from more recent experimentation, what
should such a cell be called? There are multiple dimensions,
such as function, assays used, or surface phenotype and anat-
omy, by which to develop appropriate terminology. Using the
functional dimension, a postnatal stem cell is usually defined
by the types of cells that it generates. Until direct, single-cell,
in vivo evidence is provided that indicates BMSCs can generate
any tissue other than skeletal cell types, we propose that Frie-
denstein’s BM-derived ‘‘osteogenic stem cell’’ should be called
a ‘‘skeletal stem cell,’’ consistent with the nomenclature used by
hematologists. Furthermore, ‘‘CFU-F’’ should be used to denote
a cell that is assayed as clonogenic in culture. This term clearly
indicates the experimental dimension from which the name
arises and once applied can be extended to reflect the origin
of the population in question. That is, as CFU-Fs exist in tissues
beyond BM, and likely in every postnatal connective tissue, iso-
lation of CFU-Fs from specific tissues could be denotedwith pre-
fixes such as BM-CFU-F for bone marrow, AT-CFU-F for adi-
pose tissues, etc., pending a rigorous and comparative in vivo
definition of the function of populations resident in and isolated
from other anatomical locations. Using the phenotype dimen-
sion, markers suited to identify and enrich uncultured CFU-Fs,
rather than cultured cells, will over time define subsets of cells
to be functionally probed in vivo, linking together the function,
the assay, and the phenotype. Ultimately, it would be desirable318 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.that the function, the assay, and the phenotype all be traced
back to an anatomically recognizable cell type in situ. In this
respect, the pericyte population in BM and other tissues
represents an emerging candidate.
Overall, 40 plus years of work on BMSCs and the unavoidable
swing of hypes and hopes have not taken away from the novel
biological flavor of these cells. Simultaneously functioning as
stem cells in their own right and as cells that provide the micro-
environment for other stem cells, BMSCs embody properties of
both the ‘‘seed’’ and ‘‘soil.’’ As expectations linked to BMSC
plasticity are on the wane, these unique properties of BMSCs
wax back to challenge both biology and medicine, in a quite
remarkable fashion.
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